Jan van de Winkel, Genmab CEO

Af­ter tak­ing a $73M hit, J&J part­ner Gen­mab los­es ar­bi­tra­tion over roy­al­ties on megablock­buster Darza­lex

J&J has won an ar­bi­tra­tion against Gen­mab on two mat­ters re­lat­ed to their li­cens­ing pact for dara­tu­mum­ab, the an­ti­body per­haps bet­ter known un­der the megablock­buster mul­ti­ple myelo­ma brand Darza­lex.

The long­time part­ner­ship — and the roy­al­ty stream that comes with it — with J&J’s Janssen has been cru­cial for the Copen­hagen-based biotech. But Janssen be­gan re­duc­ing its roy­al­ty pay­ments in 2020, prompt­ing Gen­mab to seek le­gal clar­i­fi­ca­tion of the ex­act amount of roy­al­ties it’s en­ti­tled to.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.